Drug Information

Drug General Information
Drug ID
D0N7LA
Former ID
DIB012609
Drug Name
BIBH 1
Drug Type
Antibody
Indication Cancer [ICD9: 140-229; ICD10:C00-C96] Phase 2 [524841]
Company
Boehringer Ingelheim
Target and Pathway
Target(s) Seprase Target Info [526622]
References
Ref 524841ClinicalTrials.gov (NCT02198274) Intravenous BIBH 1 in Patients With Metastatic Colorectal Cancer. U.S. National Institutes of Health.
Ref 526622A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res. 2003 May;9(5):1639-47.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.